Antibiotics and probiotics in inflammatory bowel disease: when to use them?
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Antibiotics and probiotics are often used as adjunctive therapy in inflammatory bowel disease. However, data are limited and randomised controlled trials are too inconsistent to provide generalised recommendations for their use in all patients with ulcerative colitis or Crohn’s disease. Antibiotics are best used in the management of infectious complications and fistulas in Crohn’s disease and, perhaps, in reducing the intensity of inflammation in luminal disease. Ciprofloxacin, metronidazole and rifaximin have been most widely used and studied. On the other hand, there appears to be a limited role for antibiotics in ulcerative colitis (UC). Probiotics are most effective in pouchitis, and may have a role in the initial therapy and maintenance of remission in mild UC; the probiotic cocktail VSL#3 has been the most widely studied. There is scant evidence of efficacy for probiotics in Crohn’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285 · cited 1×
“80 83 Conversely, an open-label RCT comparing Lactobacillus GG alone, mesal-amine and the combination of Lactobacillus GG and mesalamine failed to show any difference in relapse or adverse event rates between the three groups over a 12-month period based on UCDAI scores.”
Doron, S., & Snydman, D. R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ085 · Cited by 942 · cited 1×
“62 63 Since probiotic strains typically do not colonise the adult colon and repeated or indefinite use is required for an ongoing effect, long-term maintenance studies in IBD are needed.”
Lewis, J. D., Chen, E. Z., Baldassano, R. N., Otley, A. R., Griffiths, A. M., Lee, D., Bittinger, K., Bailey, A., Friedman, E. S., Hoffmann, C., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.09.008 · Cited by 823
Rutgeerts, P., Hiele, M., Geboes, K., Peeters, M., Penninckx, F., Aerts, R., & Kerremans, R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90121-3 · Cited by 743
Sood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.016 · Cited by 513 · cited 1×
“75 Unfortunately, this study was limited by its short duration and a high dropout rate in the placebo group.”
Tursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., Forti, G., Morini, S., Hassan, C., Pistoia, M. A., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.218 · Cited by 489 · cited 1×
“74 Studies evaluating the use of VSL”
Gupta, P., Andrew, H., Kirschner, B. S., & Guandalini, S. (2000) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200010000-00024 · Cited by 429
Kato, K., Mizuno, S., Umesaki, Y., Ishii, Y., Sugitani, M., Imaoka, A., Otsuka, M., Hasunuma, O., Kurihara, R., Iwasaki, A., et al. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02268.x · Cited by 397 · cited 1×
“77 Conversely, a Danish cross-over study of 100 patients with UC with active disease randomised to ciprofloxacin or placebo for 1 week followed by E. coli Nissle versus placebo for 7 weeks found that fewer patients on the probiotic achieved clinical remission.”
A systematic review of the safety of probiotics
Didari, T., Solki, S., Mozaffari, S., Nikfar, S., & Abdollahi, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.872627 · Cited by 367 · cited 1×
“62 63 Since probiotic strains typically do not colonise the adult colon and repeated or indefinite use is required for an ongoing effect, long-term maintenance studies in IBD are needed.”
Ohkusa, T., Kato, K., Terao, S., Chiba, T., Mabe, K., Murakami, K., Mizokami, Y., Sugiyama, T., Yanaka, A., Takeuchi, Y., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.84 · Cited by 138
Cited by
RETRACTED ARTICLE: Role of the gut microbiome in chronic diseases: a narrative review
Vijay, A., & Valdes, A. M. (2022) · European Journal of Clinical Nutrition · doi:10.1038/s41430-021-00991-6 · Cited by 361
RetractedRoy, S., & Dhaneshwar, S. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i14.2078 · Cited by 334
Zhang, Y., Tu, S., Ji, X., Wu, J., Meng, J., Gao, J., Shao, X., Shi, S., Wang, G., Qiu, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45636-x · Cited by 311
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?
Villablanca, E. J., Selin, K., & Hedin, C. R. H. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00604-y · Cited by 256
Psychological comorbidity in gastrointestinal diseases: Update on the brain-gut-microbiome axis
Person, H., & Keefer, L. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110209 · Cited by 158
Metadata
- Authors
- Abraham, B., & Quigley, E. M. M.
- Venue
- Frontline Gastroenterology
- Publisher
- BMJ
- Published
- 2019-03-22
- Volume
- 11
- Issue
- 1
- Pages
- 62-69
- ISSN
- 2041-4137 (ISSN-L)
- 2041-4145
- OpenAlex
- W2937256638
- Cited by
- 39
- References
- 10
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibiotics and probiotics in inflammatory bowel disease: when to use them? https://app.cochat.ai/papers/10.1136/flgastro-2018-101057
- The paper
- Abraham, B., & Quigley, E. M. M. (2020). Antibiotics and probiotics in inflammatory bowel disease: when to use them? Frontline Gastroenterology. https://doi.org/10.1136/flgastro-2018-101057
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.